Global RNAi Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global RNAi Therapeutics market size was valued at US$ 993 million in 2025 and is forecast to a readjusted size of US$ 3141 million by 2032 with a CAGR of 18.4% during review period.
RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.
Upstream inputs include oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics. Manufacturing relies on specialized oligo synthesis, purification, and formulation under GMP. Downstream, RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization. End markets span metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders, with hospitals and specialty clinics as primary channels.
Gross margins for RNAi therapeutics are structurally attractive but heterogeneous. Commercialized siRNA drugs can achieve ~70?85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity. Margin headwinds include high COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP. Early-stage programs show lower effective margins due to small batch sizes and high quality control intensity, while mature assets benefit from learning curves and supplier consolidation.
This report is a detailed and comprehensive analysis for global RNAi Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RNAi Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
RNAi Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe RNAi Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi Therapeutics, with revenue, gross margin, and global market share of RNAi Therapeutics from 2021 to 2026.
Chapter 3, the RNAi Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and RNAi Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi Therapeutics.
Chapter 13, to describe RNAi Therapeutics research findings and conclusion.
RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.
Upstream inputs include oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics. Manufacturing relies on specialized oligo synthesis, purification, and formulation under GMP. Downstream, RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization. End markets span metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders, with hospitals and specialty clinics as primary channels.
Gross margins for RNAi therapeutics are structurally attractive but heterogeneous. Commercialized siRNA drugs can achieve ~70?85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity. Margin headwinds include high COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP. Early-stage programs show lower effective margins due to small batch sizes and high quality control intensity, while mature assets benefit from learning curves and supplier consolidation.
This report is a detailed and comprehensive analysis for global RNAi Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RNAi Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global RNAi Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
RNAi Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Subcutaneous Injection
- Intravenous Infusion
- Synthetic siRNA
- shRNA / ddRNAi
- miRNA Mimics / Inhibitors
- bi-shRNA / bifunctional RNAi
- Self-delivering RNAi
- Fully Integrated Biopharma
- Platform-driven Licensing Model
- Co-development / Profit-sharing Model
- Others
- Cardiovascular Disease
- Genetic Disorder
- Cancer
- Other
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Silence Therapeutics
- Benitec Biopharma
- Phio Pharmaceuticals
- RXi Pharmaceuticals
- Arrakis Therapeutics
- miRagen Therapeutics
- Sylentis
- Gradalis
- Sirnaomics
- Silenseed
- Silexion Therapeutics
- Novartis
- Novo Nordisk
- Roche
- Sanofi
- Regeneron Pharmaceuticals
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe RNAi Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi Therapeutics, with revenue, gross margin, and global market share of RNAi Therapeutics from 2021 to 2026.
Chapter 3, the RNAi Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and RNAi Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi Therapeutics.
Chapter 13, to describe RNAi Therapeutics research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNAi Therapeutics by Type
1.3.1 Overview: Global RNAi Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global RNAi Therapeutics Consumption Value Market Share by Type in 2025
1.3.3 Subcutaneous Injection
1.3.4 Intravenous Infusion
1.4 Classification of RNAi Therapeutics by Molecular Modality
1.4.1 Overview: Global RNAi Therapeutics Market Size by Molecular Modality: 2021 Versus 2025 Versus 2032
1.4.2 Global RNAi Therapeutics Consumption Value Market Share by Molecular Modality in 2025
1.4.3 Synthetic siRNA
1.4.4 shRNA / ddRNAi
1.4.5 miRNA Mimics / Inhibitors
1.4.6 bi-shRNA / bifunctional RNAi
1.4.7 Self-delivering RNAi
1.5 Classification of RNAi Therapeutics by Business Model
1.5.1 Overview: Global RNAi Therapeutics Market Size by Business Model: 2021 Versus 2025 Versus 2032
1.5.2 Global RNAi Therapeutics Consumption Value Market Share by Business Model in 2025
1.5.3 Fully Integrated Biopharma
1.5.4 Platform-driven Licensing Model
1.5.5 Co-development / Profit-sharing Model
1.5.6 Others
1.6 Global RNAi Therapeutics Market by Application
1.6.1 Overview: Global RNAi Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Cardiovascular Disease
1.6.3 Genetic Disorder
1.6.4 Cancer
1.6.5 Other
1.7 Global RNAi Therapeutics Market Size & Forecast
1.8 Global RNAi Therapeutics Market Size and Forecast by Region
1.8.1 Global RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global RNAi Therapeutics Market Size by Region, (2021-2032)
1.8.3 North America RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.4 Europe RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.6 South America RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa RNAi Therapeutics Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Product and Solutions
2.1.4 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.2 Arrowhead Pharmaceuticals
2.2.1 Arrowhead Pharmaceuticals Details
2.2.2 Arrowhead Pharmaceuticals Major Business
2.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Product and Solutions
2.2.4 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Arrowhead Pharmaceuticals Recent Developments and Future Plans
2.3 Silence Therapeutics
2.3.1 Silence Therapeutics Details
2.3.2 Silence Therapeutics Major Business
2.3.3 Silence Therapeutics RNAi Therapeutics Product and Solutions
2.3.4 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Silence Therapeutics Recent Developments and Future Plans
2.4 Benitec Biopharma
2.4.1 Benitec Biopharma Details
2.4.2 Benitec Biopharma Major Business
2.4.3 Benitec Biopharma RNAi Therapeutics Product and Solutions
2.4.4 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Benitec Biopharma Recent Developments and Future Plans
2.5 Phio Pharmaceuticals
2.5.1 Phio Pharmaceuticals Details
2.5.2 Phio Pharmaceuticals Major Business
2.5.3 Phio Pharmaceuticals RNAi Therapeutics Product and Solutions
2.5.4 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Phio Pharmaceuticals Recent Developments and Future Plans
2.6 RXi Pharmaceuticals
2.6.1 RXi Pharmaceuticals Details
2.6.2 RXi Pharmaceuticals Major Business
2.6.3 RXi Pharmaceuticals RNAi Therapeutics Product and Solutions
2.6.4 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 RXi Pharmaceuticals Recent Developments and Future Plans
2.7 Arrakis Therapeutics
2.7.1 Arrakis Therapeutics Details
2.7.2 Arrakis Therapeutics Major Business
2.7.3 Arrakis Therapeutics RNAi Therapeutics Product and Solutions
2.7.4 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Arrakis Therapeutics Recent Developments and Future Plans
2.8 miRagen Therapeutics
2.8.1 miRagen Therapeutics Details
2.8.2 miRagen Therapeutics Major Business
2.8.3 miRagen Therapeutics RNAi Therapeutics Product and Solutions
2.8.4 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 miRagen Therapeutics Recent Developments and Future Plans
2.9 Sylentis
2.9.1 Sylentis Details
2.9.2 Sylentis Major Business
2.9.3 Sylentis RNAi Therapeutics Product and Solutions
2.9.4 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Sylentis Recent Developments and Future Plans
2.10 Gradalis
2.10.1 Gradalis Details
2.10.2 Gradalis Major Business
2.10.3 Gradalis RNAi Therapeutics Product and Solutions
2.10.4 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Gradalis Recent Developments and Future Plans
2.11 Sirnaomics
2.11.1 Sirnaomics Details
2.11.2 Sirnaomics Major Business
2.11.3 Sirnaomics RNAi Therapeutics Product and Solutions
2.11.4 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Sirnaomics Recent Developments and Future Plans
2.12 Silenseed
2.12.1 Silenseed Details
2.12.2 Silenseed Major Business
2.12.3 Silenseed RNAi Therapeutics Product and Solutions
2.12.4 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Silenseed Recent Developments and Future Plans
2.13 Silexion Therapeutics
2.13.1 Silexion Therapeutics Details
2.13.2 Silexion Therapeutics Major Business
2.13.3 Silexion Therapeutics RNAi Therapeutics Product and Solutions
2.13.4 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Silexion Therapeutics Recent Developments and Future Plans
2.14 Novartis
2.14.1 Novartis Details
2.14.2 Novartis Major Business
2.14.3 Novartis RNAi Therapeutics Product and Solutions
2.14.4 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Novartis Recent Developments and Future Plans
2.15 Novo Nordisk
2.15.1 Novo Nordisk Details
2.15.2 Novo Nordisk Major Business
2.15.3 Novo Nordisk RNAi Therapeutics Product and Solutions
2.15.4 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Novo Nordisk Recent Developments and Future Plans
2.16 Roche
2.16.1 Roche Details
2.16.2 Roche Major Business
2.16.3 Roche RNAi Therapeutics Product and Solutions
2.16.4 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Roche Recent Developments and Future Plans
2.17 Sanofi
2.17.1 Sanofi Details
2.17.2 Sanofi Major Business
2.17.3 Sanofi RNAi Therapeutics Product and Solutions
2.17.4 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sanofi Recent Developments and Future Plans
2.18 Regeneron Pharmaceuticals
2.18.1 Regeneron Pharmaceuticals Details
2.18.2 Regeneron Pharmaceuticals Major Business
2.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Product and Solutions
2.18.4 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNAi Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of RNAi Therapeutics by Company Revenue
3.2.2 Top 3 RNAi Therapeutics Players Market Share in 2025
3.2.3 Top 6 RNAi Therapeutics Players Market Share in 2025
3.3 RNAi Therapeutics Market: Overall Company Footprint Analysis
3.3.1 RNAi Therapeutics Market: Region Footprint
3.3.2 RNAi Therapeutics Market: Company Product Type Footprint
3.3.3 RNAi Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNAi Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global RNAi Therapeutics Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNAi Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global RNAi Therapeutics Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America RNAi Therapeutics Consumption Value by Type (2021-2032)
6.2 North America RNAi Therapeutics Market Size by Application (2021-2032)
6.3 North America RNAi Therapeutics Market Size by Country
6.3.1 North America RNAi Therapeutics Consumption Value by Country (2021-2032)
6.3.2 United States RNAi Therapeutics Market Size and Forecast (2021-2032)
6.3.3 Canada RNAi Therapeutics Market Size and Forecast (2021-2032)
6.3.4 Mexico RNAi Therapeutics Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe RNAi Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe RNAi Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe RNAi Therapeutics Market Size by Country
7.3.1 Europe RNAi Therapeutics Consumption Value by Country (2021-2032)
7.3.2 Germany RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.3 France RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.4 United Kingdom RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.5 Russia RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.6 Italy RNAi Therapeutics Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNAi Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific RNAi Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific RNAi Therapeutics Market Size by Region
8.3.1 Asia-Pacific RNAi Therapeutics Consumption Value by Region (2021-2032)
8.3.2 China RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.3 Japan RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.4 South Korea RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.5 India RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.7 Australia RNAi Therapeutics Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America RNAi Therapeutics Consumption Value by Type (2021-2032)
9.2 South America RNAi Therapeutics Consumption Value by Application (2021-2032)
9.3 South America RNAi Therapeutics Market Size by Country
9.3.1 South America RNAi Therapeutics Consumption Value by Country (2021-2032)
9.3.2 Brazil RNAi Therapeutics Market Size and Forecast (2021-2032)
9.3.3 Argentina RNAi Therapeutics Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNAi Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa RNAi Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa RNAi Therapeutics Market Size by Country
10.3.1 Middle East & Africa RNAi Therapeutics Consumption Value by Country (2021-2032)
10.3.2 Turkey RNAi Therapeutics Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia RNAi Therapeutics Market Size and Forecast (2021-2032)
10.3.4 UAE RNAi Therapeutics Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 RNAi Therapeutics Market Drivers
11.2 RNAi Therapeutics Market Restraints
11.3 RNAi Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNAi Therapeutics Industry Chain
12.2 RNAi Therapeutics Upstream Analysis
12.3 RNAi Therapeutics Midstream Analysis
12.4 RNAi Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNAi Therapeutics by Type
1.3.1 Overview: Global RNAi Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global RNAi Therapeutics Consumption Value Market Share by Type in 2025
1.3.3 Subcutaneous Injection
1.3.4 Intravenous Infusion
1.4 Classification of RNAi Therapeutics by Molecular Modality
1.4.1 Overview: Global RNAi Therapeutics Market Size by Molecular Modality: 2021 Versus 2025 Versus 2032
1.4.2 Global RNAi Therapeutics Consumption Value Market Share by Molecular Modality in 2025
1.4.3 Synthetic siRNA
1.4.4 shRNA / ddRNAi
1.4.5 miRNA Mimics / Inhibitors
1.4.6 bi-shRNA / bifunctional RNAi
1.4.7 Self-delivering RNAi
1.5 Classification of RNAi Therapeutics by Business Model
1.5.1 Overview: Global RNAi Therapeutics Market Size by Business Model: 2021 Versus 2025 Versus 2032
1.5.2 Global RNAi Therapeutics Consumption Value Market Share by Business Model in 2025
1.5.3 Fully Integrated Biopharma
1.5.4 Platform-driven Licensing Model
1.5.5 Co-development / Profit-sharing Model
1.5.6 Others
1.6 Global RNAi Therapeutics Market by Application
1.6.1 Overview: Global RNAi Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Cardiovascular Disease
1.6.3 Genetic Disorder
1.6.4 Cancer
1.6.5 Other
1.7 Global RNAi Therapeutics Market Size & Forecast
1.8 Global RNAi Therapeutics Market Size and Forecast by Region
1.8.1 Global RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global RNAi Therapeutics Market Size by Region, (2021-2032)
1.8.3 North America RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.4 Europe RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.6 South America RNAi Therapeutics Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa RNAi Therapeutics Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Product and Solutions
2.1.4 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.2 Arrowhead Pharmaceuticals
2.2.1 Arrowhead Pharmaceuticals Details
2.2.2 Arrowhead Pharmaceuticals Major Business
2.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Product and Solutions
2.2.4 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Arrowhead Pharmaceuticals Recent Developments and Future Plans
2.3 Silence Therapeutics
2.3.1 Silence Therapeutics Details
2.3.2 Silence Therapeutics Major Business
2.3.3 Silence Therapeutics RNAi Therapeutics Product and Solutions
2.3.4 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Silence Therapeutics Recent Developments and Future Plans
2.4 Benitec Biopharma
2.4.1 Benitec Biopharma Details
2.4.2 Benitec Biopharma Major Business
2.4.3 Benitec Biopharma RNAi Therapeutics Product and Solutions
2.4.4 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Benitec Biopharma Recent Developments and Future Plans
2.5 Phio Pharmaceuticals
2.5.1 Phio Pharmaceuticals Details
2.5.2 Phio Pharmaceuticals Major Business
2.5.3 Phio Pharmaceuticals RNAi Therapeutics Product and Solutions
2.5.4 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Phio Pharmaceuticals Recent Developments and Future Plans
2.6 RXi Pharmaceuticals
2.6.1 RXi Pharmaceuticals Details
2.6.2 RXi Pharmaceuticals Major Business
2.6.3 RXi Pharmaceuticals RNAi Therapeutics Product and Solutions
2.6.4 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 RXi Pharmaceuticals Recent Developments and Future Plans
2.7 Arrakis Therapeutics
2.7.1 Arrakis Therapeutics Details
2.7.2 Arrakis Therapeutics Major Business
2.7.3 Arrakis Therapeutics RNAi Therapeutics Product and Solutions
2.7.4 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Arrakis Therapeutics Recent Developments and Future Plans
2.8 miRagen Therapeutics
2.8.1 miRagen Therapeutics Details
2.8.2 miRagen Therapeutics Major Business
2.8.3 miRagen Therapeutics RNAi Therapeutics Product and Solutions
2.8.4 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 miRagen Therapeutics Recent Developments and Future Plans
2.9 Sylentis
2.9.1 Sylentis Details
2.9.2 Sylentis Major Business
2.9.3 Sylentis RNAi Therapeutics Product and Solutions
2.9.4 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Sylentis Recent Developments and Future Plans
2.10 Gradalis
2.10.1 Gradalis Details
2.10.2 Gradalis Major Business
2.10.3 Gradalis RNAi Therapeutics Product and Solutions
2.10.4 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Gradalis Recent Developments and Future Plans
2.11 Sirnaomics
2.11.1 Sirnaomics Details
2.11.2 Sirnaomics Major Business
2.11.3 Sirnaomics RNAi Therapeutics Product and Solutions
2.11.4 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Sirnaomics Recent Developments and Future Plans
2.12 Silenseed
2.12.1 Silenseed Details
2.12.2 Silenseed Major Business
2.12.3 Silenseed RNAi Therapeutics Product and Solutions
2.12.4 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Silenseed Recent Developments and Future Plans
2.13 Silexion Therapeutics
2.13.1 Silexion Therapeutics Details
2.13.2 Silexion Therapeutics Major Business
2.13.3 Silexion Therapeutics RNAi Therapeutics Product and Solutions
2.13.4 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Silexion Therapeutics Recent Developments and Future Plans
2.14 Novartis
2.14.1 Novartis Details
2.14.2 Novartis Major Business
2.14.3 Novartis RNAi Therapeutics Product and Solutions
2.14.4 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Novartis Recent Developments and Future Plans
2.15 Novo Nordisk
2.15.1 Novo Nordisk Details
2.15.2 Novo Nordisk Major Business
2.15.3 Novo Nordisk RNAi Therapeutics Product and Solutions
2.15.4 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Novo Nordisk Recent Developments and Future Plans
2.16 Roche
2.16.1 Roche Details
2.16.2 Roche Major Business
2.16.3 Roche RNAi Therapeutics Product and Solutions
2.16.4 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Roche Recent Developments and Future Plans
2.17 Sanofi
2.17.1 Sanofi Details
2.17.2 Sanofi Major Business
2.17.3 Sanofi RNAi Therapeutics Product and Solutions
2.17.4 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sanofi Recent Developments and Future Plans
2.18 Regeneron Pharmaceuticals
2.18.1 Regeneron Pharmaceuticals Details
2.18.2 Regeneron Pharmaceuticals Major Business
2.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Product and Solutions
2.18.4 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RNAi Therapeutics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of RNAi Therapeutics by Company Revenue
3.2.2 Top 3 RNAi Therapeutics Players Market Share in 2025
3.2.3 Top 6 RNAi Therapeutics Players Market Share in 2025
3.3 RNAi Therapeutics Market: Overall Company Footprint Analysis
3.3.1 RNAi Therapeutics Market: Region Footprint
3.3.2 RNAi Therapeutics Market: Company Product Type Footprint
3.3.3 RNAi Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global RNAi Therapeutics Consumption Value and Market Share by Type (2021-2026)
4.2 Global RNAi Therapeutics Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RNAi Therapeutics Consumption Value Market Share by Application (2021-2026)
5.2 Global RNAi Therapeutics Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America RNAi Therapeutics Consumption Value by Type (2021-2032)
6.2 North America RNAi Therapeutics Market Size by Application (2021-2032)
6.3 North America RNAi Therapeutics Market Size by Country
6.3.1 North America RNAi Therapeutics Consumption Value by Country (2021-2032)
6.3.2 United States RNAi Therapeutics Market Size and Forecast (2021-2032)
6.3.3 Canada RNAi Therapeutics Market Size and Forecast (2021-2032)
6.3.4 Mexico RNAi Therapeutics Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe RNAi Therapeutics Consumption Value by Type (2021-2032)
7.2 Europe RNAi Therapeutics Consumption Value by Application (2021-2032)
7.3 Europe RNAi Therapeutics Market Size by Country
7.3.1 Europe RNAi Therapeutics Consumption Value by Country (2021-2032)
7.3.2 Germany RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.3 France RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.4 United Kingdom RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.5 Russia RNAi Therapeutics Market Size and Forecast (2021-2032)
7.3.6 Italy RNAi Therapeutics Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific RNAi Therapeutics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific RNAi Therapeutics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific RNAi Therapeutics Market Size by Region
8.3.1 Asia-Pacific RNAi Therapeutics Consumption Value by Region (2021-2032)
8.3.2 China RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.3 Japan RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.4 South Korea RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.5 India RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia RNAi Therapeutics Market Size and Forecast (2021-2032)
8.3.7 Australia RNAi Therapeutics Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America RNAi Therapeutics Consumption Value by Type (2021-2032)
9.2 South America RNAi Therapeutics Consumption Value by Application (2021-2032)
9.3 South America RNAi Therapeutics Market Size by Country
9.3.1 South America RNAi Therapeutics Consumption Value by Country (2021-2032)
9.3.2 Brazil RNAi Therapeutics Market Size and Forecast (2021-2032)
9.3.3 Argentina RNAi Therapeutics Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RNAi Therapeutics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa RNAi Therapeutics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa RNAi Therapeutics Market Size by Country
10.3.1 Middle East & Africa RNAi Therapeutics Consumption Value by Country (2021-2032)
10.3.2 Turkey RNAi Therapeutics Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia RNAi Therapeutics Market Size and Forecast (2021-2032)
10.3.4 UAE RNAi Therapeutics Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 RNAi Therapeutics Market Drivers
11.2 RNAi Therapeutics Market Restraints
11.3 RNAi Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RNAi Therapeutics Industry Chain
12.2 RNAi Therapeutics Upstream Analysis
12.3 RNAi Therapeutics Midstream Analysis
12.4 RNAi Therapeutics Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global RNAi Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global RNAi Therapeutics Consumption Value by Molecular Modality, (USD Million), 2021 & 2025 & 2032
Table 3. Global RNAi Therapeutics Consumption Value by Business Model, (USD Million), 2021 & 2025 & 2032
Table 4. Global RNAi Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global RNAi Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global RNAi Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 8. Alnylam Pharmaceuticals Major Business
Table 9. Alnylam Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 10. Alnylam Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Alnylam Pharmaceuticals Recent Developments and Future Plans
Table 12. Arrowhead Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 13. Arrowhead Pharmaceuticals Major Business
Table 14. Arrowhead Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 15. Arrowhead Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Arrowhead Pharmaceuticals Recent Developments and Future Plans
Table 17. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 18. Silence Therapeutics Major Business
Table 19. Silence Therapeutics RNAi Therapeutics Product and Solutions
Table 20. Silence Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Benitec Biopharma Company Information, Head Office, and Major Competitors
Table 22. Benitec Biopharma Major Business
Table 23. Benitec Biopharma RNAi Therapeutics Product and Solutions
Table 24. Benitec Biopharma RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Benitec Biopharma Recent Developments and Future Plans
Table 26. Phio Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Phio Pharmaceuticals Major Business
Table 28. Phio Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 29. Phio Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Phio Pharmaceuticals Recent Developments and Future Plans
Table 31. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 32. RXi Pharmaceuticals Major Business
Table 33. RXi Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 34. RXi Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. RXi Pharmaceuticals Recent Developments and Future Plans
Table 36. Arrakis Therapeutics Company Information, Head Office, and Major Competitors
Table 37. Arrakis Therapeutics Major Business
Table 38. Arrakis Therapeutics RNAi Therapeutics Product and Solutions
Table 39. Arrakis Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Arrakis Therapeutics Recent Developments and Future Plans
Table 41. miRagen Therapeutics Company Information, Head Office, and Major Competitors
Table 42. miRagen Therapeutics Major Business
Table 43. miRagen Therapeutics RNAi Therapeutics Product and Solutions
Table 44. miRagen Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. miRagen Therapeutics Recent Developments and Future Plans
Table 46. Sylentis Company Information, Head Office, and Major Competitors
Table 47. Sylentis Major Business
Table 48. Sylentis RNAi Therapeutics Product and Solutions
Table 49. Sylentis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Sylentis Recent Developments and Future Plans
Table 51. Gradalis Company Information, Head Office, and Major Competitors
Table 52. Gradalis Major Business
Table 53. Gradalis RNAi Therapeutics Product and Solutions
Table 54. Gradalis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Gradalis Recent Developments and Future Plans
Table 56. Sirnaomics Company Information, Head Office, and Major Competitors
Table 57. Sirnaomics Major Business
Table 58. Sirnaomics RNAi Therapeutics Product and Solutions
Table 59. Sirnaomics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Sirnaomics Recent Developments and Future Plans
Table 61. Silenseed Company Information, Head Office, and Major Competitors
Table 62. Silenseed Major Business
Table 63. Silenseed RNAi Therapeutics Product and Solutions
Table 64. Silenseed RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Silenseed Recent Developments and Future Plans
Table 66. Silexion Therapeutics Company Information, Head Office, and Major Competitors
Table 67. Silexion Therapeutics Major Business
Table 68. Silexion Therapeutics RNAi Therapeutics Product and Solutions
Table 69. Silexion Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Silexion Therapeutics Recent Developments and Future Plans
Table 71. Novartis Company Information, Head Office, and Major Competitors
Table 72. Novartis Major Business
Table 73. Novartis RNAi Therapeutics Product and Solutions
Table 74. Novartis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Novartis Recent Developments and Future Plans
Table 76. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 77. Novo Nordisk Major Business
Table 78. Novo Nordisk RNAi Therapeutics Product and Solutions
Table 79. Novo Nordisk RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Novo Nordisk Recent Developments and Future Plans
Table 81. Roche Company Information, Head Office, and Major Competitors
Table 82. Roche Major Business
Table 83. Roche RNAi Therapeutics Product and Solutions
Table 84. Roche RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Roche Recent Developments and Future Plans
Table 86. Sanofi Company Information, Head Office, and Major Competitors
Table 87. Sanofi Major Business
Table 88. Sanofi RNAi Therapeutics Product and Solutions
Table 89. Sanofi RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Sanofi Recent Developments and Future Plans
Table 91. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 92. Regeneron Pharmaceuticals Major Business
Table 93. Regeneron Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 94. Regeneron Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Regeneron Pharmaceuticals Recent Developments and Future Plans
Table 96. Global RNAi Therapeutics Revenue (USD Million) by Players (2021-2026)
Table 97. Global RNAi Therapeutics Revenue Share by Players (2021-2026)
Table 98. Breakdown of RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 99. Market Position of Players in RNAi Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 100. Head Office of Key RNAi Therapeutics Players
Table 101. RNAi Therapeutics Market: Company Product Type Footprint
Table 102. RNAi Therapeutics Market: Company Product Application Footprint
Table 103. RNAi Therapeutics New Market Entrants and Barriers to Market Entry
Table 104. RNAi Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 105. Global RNAi Therapeutics Consumption Value (USD Million) by Type (2021-2026)
Table 106. Global RNAi Therapeutics Consumption Value Share by Type (2021-2026)
Table 107. Global RNAi Therapeutics Consumption Value Forecast by Type (2027-2032)
Table 108. Global RNAi Therapeutics Consumption Value by Application (2021-2026)
Table 109. Global RNAi Therapeutics Consumption Value Forecast by Application (2027-2032)
Table 110. North America RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 111. North America RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 112. North America RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 113. North America RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 114. North America RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 115. North America RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Europe RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 117. Europe RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 118. Europe RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 119. Europe RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 120. Europe RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 121. Europe RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 122. Asia-Pacific RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 123. Asia-Pacific RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 124. Asia-Pacific RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 125. Asia-Pacific RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 126. Asia-Pacific RNAi Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 127. Asia-Pacific RNAi Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 128. South America RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 129. South America RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 130. South America RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 131. South America RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 132. South America RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 133. South America RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 134. Middle East & Africa RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 135. Middle East & Africa RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 136. Middle East & Africa RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 137. Middle East & Africa RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 138. Middle East & Africa RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 139. Middle East & Africa RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 140. Global Key Players of RNAi Therapeutics Upstream (Raw Materials)
Table 141. Global RNAi Therapeutics Typical Customers
Table 1. Global RNAi Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global RNAi Therapeutics Consumption Value by Molecular Modality, (USD Million), 2021 & 2025 & 2032
Table 3. Global RNAi Therapeutics Consumption Value by Business Model, (USD Million), 2021 & 2025 & 2032
Table 4. Global RNAi Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global RNAi Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global RNAi Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 8. Alnylam Pharmaceuticals Major Business
Table 9. Alnylam Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 10. Alnylam Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Alnylam Pharmaceuticals Recent Developments and Future Plans
Table 12. Arrowhead Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 13. Arrowhead Pharmaceuticals Major Business
Table 14. Arrowhead Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 15. Arrowhead Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Arrowhead Pharmaceuticals Recent Developments and Future Plans
Table 17. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 18. Silence Therapeutics Major Business
Table 19. Silence Therapeutics RNAi Therapeutics Product and Solutions
Table 20. Silence Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Benitec Biopharma Company Information, Head Office, and Major Competitors
Table 22. Benitec Biopharma Major Business
Table 23. Benitec Biopharma RNAi Therapeutics Product and Solutions
Table 24. Benitec Biopharma RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Benitec Biopharma Recent Developments and Future Plans
Table 26. Phio Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Phio Pharmaceuticals Major Business
Table 28. Phio Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 29. Phio Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Phio Pharmaceuticals Recent Developments and Future Plans
Table 31. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 32. RXi Pharmaceuticals Major Business
Table 33. RXi Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 34. RXi Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. RXi Pharmaceuticals Recent Developments and Future Plans
Table 36. Arrakis Therapeutics Company Information, Head Office, and Major Competitors
Table 37. Arrakis Therapeutics Major Business
Table 38. Arrakis Therapeutics RNAi Therapeutics Product and Solutions
Table 39. Arrakis Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Arrakis Therapeutics Recent Developments and Future Plans
Table 41. miRagen Therapeutics Company Information, Head Office, and Major Competitors
Table 42. miRagen Therapeutics Major Business
Table 43. miRagen Therapeutics RNAi Therapeutics Product and Solutions
Table 44. miRagen Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. miRagen Therapeutics Recent Developments and Future Plans
Table 46. Sylentis Company Information, Head Office, and Major Competitors
Table 47. Sylentis Major Business
Table 48. Sylentis RNAi Therapeutics Product and Solutions
Table 49. Sylentis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Sylentis Recent Developments and Future Plans
Table 51. Gradalis Company Information, Head Office, and Major Competitors
Table 52. Gradalis Major Business
Table 53. Gradalis RNAi Therapeutics Product and Solutions
Table 54. Gradalis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Gradalis Recent Developments and Future Plans
Table 56. Sirnaomics Company Information, Head Office, and Major Competitors
Table 57. Sirnaomics Major Business
Table 58. Sirnaomics RNAi Therapeutics Product and Solutions
Table 59. Sirnaomics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Sirnaomics Recent Developments and Future Plans
Table 61. Silenseed Company Information, Head Office, and Major Competitors
Table 62. Silenseed Major Business
Table 63. Silenseed RNAi Therapeutics Product and Solutions
Table 64. Silenseed RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Silenseed Recent Developments and Future Plans
Table 66. Silexion Therapeutics Company Information, Head Office, and Major Competitors
Table 67. Silexion Therapeutics Major Business
Table 68. Silexion Therapeutics RNAi Therapeutics Product and Solutions
Table 69. Silexion Therapeutics RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Silexion Therapeutics Recent Developments and Future Plans
Table 71. Novartis Company Information, Head Office, and Major Competitors
Table 72. Novartis Major Business
Table 73. Novartis RNAi Therapeutics Product and Solutions
Table 74. Novartis RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Novartis Recent Developments and Future Plans
Table 76. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 77. Novo Nordisk Major Business
Table 78. Novo Nordisk RNAi Therapeutics Product and Solutions
Table 79. Novo Nordisk RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Novo Nordisk Recent Developments and Future Plans
Table 81. Roche Company Information, Head Office, and Major Competitors
Table 82. Roche Major Business
Table 83. Roche RNAi Therapeutics Product and Solutions
Table 84. Roche RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Roche Recent Developments and Future Plans
Table 86. Sanofi Company Information, Head Office, and Major Competitors
Table 87. Sanofi Major Business
Table 88. Sanofi RNAi Therapeutics Product and Solutions
Table 89. Sanofi RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Sanofi Recent Developments and Future Plans
Table 91. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 92. Regeneron Pharmaceuticals Major Business
Table 93. Regeneron Pharmaceuticals RNAi Therapeutics Product and Solutions
Table 94. Regeneron Pharmaceuticals RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Regeneron Pharmaceuticals Recent Developments and Future Plans
Table 96. Global RNAi Therapeutics Revenue (USD Million) by Players (2021-2026)
Table 97. Global RNAi Therapeutics Revenue Share by Players (2021-2026)
Table 98. Breakdown of RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 99. Market Position of Players in RNAi Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 100. Head Office of Key RNAi Therapeutics Players
Table 101. RNAi Therapeutics Market: Company Product Type Footprint
Table 102. RNAi Therapeutics Market: Company Product Application Footprint
Table 103. RNAi Therapeutics New Market Entrants and Barriers to Market Entry
Table 104. RNAi Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 105. Global RNAi Therapeutics Consumption Value (USD Million) by Type (2021-2026)
Table 106. Global RNAi Therapeutics Consumption Value Share by Type (2021-2026)
Table 107. Global RNAi Therapeutics Consumption Value Forecast by Type (2027-2032)
Table 108. Global RNAi Therapeutics Consumption Value by Application (2021-2026)
Table 109. Global RNAi Therapeutics Consumption Value Forecast by Application (2027-2032)
Table 110. North America RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 111. North America RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 112. North America RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 113. North America RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 114. North America RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 115. North America RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Europe RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 117. Europe RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 118. Europe RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 119. Europe RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 120. Europe RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 121. Europe RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 122. Asia-Pacific RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 123. Asia-Pacific RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 124. Asia-Pacific RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 125. Asia-Pacific RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 126. Asia-Pacific RNAi Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 127. Asia-Pacific RNAi Therapeutics Consumption Value by Region (2027-2032) & (USD Million)
Table 128. South America RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 129. South America RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 130. South America RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 131. South America RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 132. South America RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 133. South America RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 134. Middle East & Africa RNAi Therapeutics Consumption Value by Type (2021-2026) & (USD Million)
Table 135. Middle East & Africa RNAi Therapeutics Consumption Value by Type (2027-2032) & (USD Million)
Table 136. Middle East & Africa RNAi Therapeutics Consumption Value by Application (2021-2026) & (USD Million)
Table 137. Middle East & Africa RNAi Therapeutics Consumption Value by Application (2027-2032) & (USD Million)
Table 138. Middle East & Africa RNAi Therapeutics Consumption Value by Country (2021-2026) & (USD Million)
Table 139. Middle East & Africa RNAi Therapeutics Consumption Value by Country (2027-2032) & (USD Million)
Table 140. Global Key Players of RNAi Therapeutics Upstream (Raw Materials)
Table 141. Global RNAi Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. RNAi Therapeutics Picture
Figure 2. Global RNAi Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global RNAi Therapeutics Consumption Value Market Share by Type in 2025
Figure 4. Subcutaneous Injection
Figure 5. Intravenous Infusion
Figure 6. Global RNAi Therapeutics Consumption Value by Molecular Modality, (USD Million), 2021 & 2025 & 2032
Figure 7. Global RNAi Therapeutics Consumption Value Market Share by Molecular Modality in 2025
Figure 8. Synthetic siRNA
Figure 9. shRNA / ddRNAi
Figure 10. miRNA Mimics / Inhibitors
Figure 11. bi-shRNA / bifunctional RNAi
Figure 12. Self-delivering RNAi
Figure 13. Global RNAi Therapeutics Consumption Value by Business Model, (USD Million), 2021 & 2025 & 2032
Figure 14. Global RNAi Therapeutics Consumption Value Market Share by Business Model in 2025
Figure 15. Fully Integrated Biopharma
Figure 16. Platform-driven Licensing Model
Figure 17. Co-development / Profit-sharing Model
Figure 18. Others
Figure 19. Global RNAi Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 20. RNAi Therapeutics Consumption Value Market Share by Application in 2025
Figure 21. Cardiovascular Disease Picture
Figure 22. Genetic Disorder Picture
Figure 23. Cancer Picture
Figure 24. Other Picture
Figure 25. Global RNAi Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global RNAi Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market RNAi Therapeutics Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global RNAi Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 29. Global RNAi Therapeutics Consumption Value Market Share by Region in 2025
Figure 30. North America RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 33. South America RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global RNAi Therapeutics Revenue Share by Players in 2025
Figure 37. RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of RNAi Therapeutics by Player Revenue in 2025
Figure 39. Top 3 RNAi Therapeutics Players Market Share in 2025
Figure 40. Top 6 RNAi Therapeutics Players Market Share in 2025
Figure 41. Global RNAi Therapeutics Consumption Value Share by Type (2021-2026)
Figure 42. Global RNAi Therapeutics Market Share Forecast by Type (2027-2032)
Figure 43. Global RNAi Therapeutics Consumption Value Share by Application (2021-2026)
Figure 44. Global RNAi Therapeutics Market Share Forecast by Application (2027-2032)
Figure 45. North America RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 46. North America RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 47. North America RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 48. United States RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. France RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 62. China RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. India RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 68. South America RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 69. South America RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 70. South America RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 79. RNAi Therapeutics Market Drivers
Figure 80. RNAi Therapeutics Market Restraints
Figure 81. RNAi Therapeutics Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. RNAi Therapeutics Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. RNAi Therapeutics Picture
Figure 2. Global RNAi Therapeutics Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global RNAi Therapeutics Consumption Value Market Share by Type in 2025
Figure 4. Subcutaneous Injection
Figure 5. Intravenous Infusion
Figure 6. Global RNAi Therapeutics Consumption Value by Molecular Modality, (USD Million), 2021 & 2025 & 2032
Figure 7. Global RNAi Therapeutics Consumption Value Market Share by Molecular Modality in 2025
Figure 8. Synthetic siRNA
Figure 9. shRNA / ddRNAi
Figure 10. miRNA Mimics / Inhibitors
Figure 11. bi-shRNA / bifunctional RNAi
Figure 12. Self-delivering RNAi
Figure 13. Global RNAi Therapeutics Consumption Value by Business Model, (USD Million), 2021 & 2025 & 2032
Figure 14. Global RNAi Therapeutics Consumption Value Market Share by Business Model in 2025
Figure 15. Fully Integrated Biopharma
Figure 16. Platform-driven Licensing Model
Figure 17. Co-development / Profit-sharing Model
Figure 18. Others
Figure 19. Global RNAi Therapeutics Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 20. RNAi Therapeutics Consumption Value Market Share by Application in 2025
Figure 21. Cardiovascular Disease Picture
Figure 22. Genetic Disorder Picture
Figure 23. Cancer Picture
Figure 24. Other Picture
Figure 25. Global RNAi Therapeutics Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global RNAi Therapeutics Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market RNAi Therapeutics Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global RNAi Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 29. Global RNAi Therapeutics Consumption Value Market Share by Region in 2025
Figure 30. North America RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 33. South America RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global RNAi Therapeutics Revenue Share by Players in 2025
Figure 37. RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of RNAi Therapeutics by Player Revenue in 2025
Figure 39. Top 3 RNAi Therapeutics Players Market Share in 2025
Figure 40. Top 6 RNAi Therapeutics Players Market Share in 2025
Figure 41. Global RNAi Therapeutics Consumption Value Share by Type (2021-2026)
Figure 42. Global RNAi Therapeutics Market Share Forecast by Type (2027-2032)
Figure 43. Global RNAi Therapeutics Consumption Value Share by Application (2021-2026)
Figure 44. Global RNAi Therapeutics Market Share Forecast by Application (2027-2032)
Figure 45. North America RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 46. North America RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 47. North America RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 48. United States RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 55. France RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific RNAi Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 62. China RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 65. India RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 68. South America RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 69. South America RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 70. South America RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa RNAi Therapeutics Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE RNAi Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 79. RNAi Therapeutics Market Drivers
Figure 80. RNAi Therapeutics Market Restraints
Figure 81. RNAi Therapeutics Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. RNAi Therapeutics Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source
